Table 3.
Prevalence of CPIC level A and B drugs prescribed after PCI and antiplatelet initiation among patients with at least 1, 3, and 5 years' follow‐up data in MarketScan (2008–2015)
| Antiplatelet therapy initiators | ||
|---|---|---|
| Number of prescriptions other than antiplatelet therapy in the 1, 2, and 5‐year follow‐up periods | CPIC Level A or B Drug n (%) | CPIC Level A Drug n (%) |
| 1‐year follow‐up | N = 105,547 | |
| 0 prescriptions | 52,748 (50.0) | 67,254 (63.7) |
| 1–2 | 37,760 (35.8) | 32,804 (31.1) |
| 3–4 | 11,757 (11.1) | 4,782 (4.5) |
| 5–6 | 2,690 (2.5) | 604 (0.6) |
| > 6 | 592 (0.6) | 103 (0.1) |
| 3‐year follow‐up | N = 39,962 | |
| 0 prescriptions | 15,631 (39.1) | 20,969 (52.5) |
| 1–2 | 15,706 (39.3) | 15,264 (38.2) |
| 3–4 | 6,361 (16.0) | 3,328 (8.3) |
| 5–6 | 1,816 (4.5) | 370 (0.9) |
| > 6 | 448 (1.1) | 31 (0.1) |
| 5‐year follow‐up | N = 12,462 | |
| 0 prescriptions | 3,989 (32.0) | 5,577 (44.8) |
| 1–2 | 5,050 (40.5) | 5,299 (42.5) |
| 3–4 | 2,397 (19.2) | 1,389 (11.1) |
| 5–6 | 786 (6.3) | 180 (1.4) |
| > 6 | 240 (2.0) | 17 (0.1) |
CPIC, Clinical Pharmacogenetics Implementation Consortium; PCI, percutaneous coronary intervention.
Zero, 1–2, 3–4, 5–6, and > 6 prescriptions refer to the number of prescriptions for drugs with pharmacogenetic evidence (CPIC level A or B or CPIC level A only) that were prescribed in addition to antiplatelet therapy for cohorts with at least 1 year, 3 years, and 5 years of continuous enrollment.